Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal
Gilead Sciences is acquiring Tubulis GmbH for $3.15 billion upfront, with potential additional milestone payments, to bolster its oncology pipeline with TUB-040, an antibody-drug conjugate for ovarian cancer. This acquisition follows other recent deals, including Ouro Medicines and Arcellx, highlighting Gilead's strategy to expand its portfolio in oncology and autoimmune diseases. Despite the strategic acquisitions, Gilead's stock (GILD) showed short-term weakness but maintained a positive long-term outlook.
Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis
Gilead Sciences has acquired German antibody-drug conjugate (ADC) specialist Tubulis GmbH for $3.15 billion in cash plus up to $1.85 billion in potential milestone payments, marking its latest deal to bolster its oncology pipeline. This acquisition brings Tubulis' lead candidate TUB-040, currently in Phase 1b/2 development for ovarian cancer and non-small cell lung cancer, into Gilead's portfolio. Tubulis will operate as a dedicated ADC research and development organization within Gilead, leveraging a partnership initially formed in December 2024.
Gilead Swallows Another Partner, Paying up to $5.3B for ADC Specialist Tubulis
Gilead Sciences is acquiring German antibody-drug conjugate (ADC) specialist Tubulis GmbH for $3.15 billion in cash plus up to $1.85 billion in potential milestone payments. This acquisition, Gilead's third of the year, aims to bolster its oncology pipeline and includes a promising mid-stage ovarian cancer candidate, TUB-040, which has shown a 59% overall response rate in platinum-resistant ovarian cancer. Tubulis will operate as a dedicated ADC research and development organization within Gilead, leveraging its platform that Gilead was already familiar with through a prior partnership.
Press Release: EQT Life Sciences to Exit Minority Stake in Tubulis via Sale to Gilead Sciences for up to USD 5.0 Billion
EQT Life Sciences is selling its minority stake in Tubulis to Gilead Sciences, which is acquiring the company for up to USD 5.0 billion. Tubulis specializes in advanced antibody-drug conjugate (ADC) technologies, and this acquisition is expected to bolster Gilead's oncology pipeline. EQT Life Sciences initially invested in Tubulis in 2021 as part of a Series A financing round.
Gilead Enters $5 Billion Agreement to Acquire Tubulis
Gilead Sciences has announced an agreement to acquire Tubulis GmbH for up to $5 billion, significantly expanding its oncology pipeline with two clinical-stage antibody-drug conjugate (ADC) assets and a next-generation conjugation platform. This acquisition will establish Munich as Gilead's dedicated ADC research hub and builds on an existing collaboration between the two companies. The deal underscores Gilead's accelerated corporate buildout in oncology, positioning it more strongly in the competitive ADC landscape.
Gilead to acquire Tubulis GmbH for $5B (GILD:NASDAQ)
Gilead Sciences, Inc. announced its intention to acquire German biotechnology firm Tubulis GmbH for $5 billion. This acquisition is aimed at strengthening Gilead's oncology pipeline, specifically by gaining access to Tubulis's antibody-drug conjugate therapies, including those developed for ovarian cancer.
Gilead Sciences to buy German biotech group Tubulis for up to $5bn
Gilead Sciences announced its agreement to acquire the German clinical-stage biotechnology group Tubulis for up to $5 billion. This acquisition will expand Gilead's oncology pipeline, particularly its antibody-drug conjugate (ADC) capabilities, adding next-generation assets and platforms. Tubulis's lead asset, TUB-040, currently in Phase 1b/2 development for ovarian cancer and NSCLC, and TUB-030, a 5T4 targeted ADC, are key to this strategic move.
Gilead to Buy German Biotech Tubulis for Up to $5 Billion
Gilead Sciences has announced its agreement to acquire German biotech company Tubulis GmbH in a cash deal valued at up to $5 billion. This acquisition aims to bolster Gilead's cancer drug pipeline, specifically by investing in antibody-drug conjugates, a targeted form of cancer treatment.
Primary Sclerosing Cholangitis Market is expected to Hit US$ 987.26 million by 2033 | Major Companies - Chemomab Therapeutics Ltd., Mirum Pharmaceuticals, Inc., Ipsen S.A., Gilead Sciences, Inc.
The global Primary Sclerosing Cholangitis (PSC) market, valued at US$ 385.67 million in 2025, is projected to reach US$ 987.26 million by 2033, growing at a CAGR of 12.21% from 2026-2033. This growth is driven by increasing disease prevalence, heightened awareness, and advancements in targeted therapies and diagnostics for PSC. Key players in this market include Chemomab Therapeutics Ltd., Mirum Pharmaceuticals, Inc., Ipsen S.A., and Gilead Sciences, Inc., with recent industry developments focused on expanding transplant care, biologic-based therapies, and strategic acquisitions to bolster rare liver disease pipelines.
Tractor Supply Company (TSCO) PT Lowered to $55 at Evercore ISI
Evercore ISI analyst Oliver Wintermantel has lowered the price target for Tractor Supply Company (TSCO) to $55. This detail is part of a premium article, requiring a StreetInsider.com Premium subscription to access the full content.
Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion
Gilead Sciences has agreed to acquire German clinical-stage biotechnology company Tubulis for a total of up to $5 billion. The deal, comprising an initial $3.15 billion cash payment and up to $1.85 billion in contingent milestone payments, aims to strengthen Gilead's oncology pipeline. Tubulis specializes in developing next-generation antibody-drug conjugates (ADCs) for cancer treatment, with lead assets targeting platinum-resistant ovarian cancer, non-small cell lung cancer, and various solid tumor types.
Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion
Gilead Sciences has announced an agreement to acquire German clinical-stage biotechnology company Tubulis for up to $5 billion. The deal involves an initial cash payment of $3.15 billion and up to $1.85 billion in contingent milestone payments. This acquisition aims to strengthen Gilead's oncology pipeline by adding Tubulis's next-generation antibody-drug conjugates (ADCs).
Gilead Sciences to acquire Tubulis for up to $5 billion
Gilead Sciences announced its intent to acquire German biotechnology company Tubulis GmbH for an upfront cash payment of $3.15 billion and up to an additional $1.85 billion in contingent milestone payments. Tubulis specializes in developing next-generation antibody-drug conjugates (ADCs) for cancer treatment. This acquisition, expected to close in Q2 2026, aims to significantly advance Gilead's oncology pipeline and establish a dedicated ADC research hub in Munich.
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
Gilead Sciences, Inc. announced its definitive agreement to acquire Tubulis GmbH for $3.15 billion upfront and up to $1.85 billion in contingent payments, significantly expanding Gilead's oncology pipeline with next-generation antibody-drug conjugates (ADCs). The acquisition includes Tubulis’ lead asset, TUB-040, for ovarian and non-small cell lung cancer, and will establish Tubulis as Gilead's dedicated ADC research hub in Munich. This move strengthens Gilead's position in developing innovative cancer treatments and builds on their existing two-year collaboration.
Gilead Sciences To Acquire Tubulis GmbH
Gilead Sciences is set to acquire Tubulis GmbH. This news was reported by Reuters and is less than a minute read. The acquisition involves the company Gilead Sciences (GILD).
Nurix Therapeutics to Participate in Upcoming Investor Conference
Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced that its president and chief executive officer, Arthur Sands, M.D., Ph.D., will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. The company is a clinical-stage biopharmaceutical firm focused on targeted protein degradation medicines for cancer and autoimmune diseases. Nurix has a pipeline of wholly-owned and partnered programs, leveraging its AI-integrated discovery engine and ligase expertise.
Galapagos NV (GLPG) signs agreement with Gilead on Ouro Medicines assets
Galapagos NV has signed an agreement with Gilead Sciences regarding Ouro Medicines' assets. This collaboration involves Gilead gaining access to potentially transformative therapeutic programs developed by Ouro. The financial terms and specific assets involved are expected to be detailed further.
Biogen Paid a 140% Premium for Apellis. Was the $5.6B Deal Worth It?
Biogen acquired Apellis for $5.6 billion, representing a 140% premium, a deal met with skepticism from the market due to Apellis's flagship drug SYFOVRE experiencing a revenue decline. While SYFOVRE faces challenges, the acquisition's strategic value is bolstered by EMPAVELI, approved for rare kidney diseases, and the unpriced optionality of felzartamab, a drug in Phase 3 trials for kidney diseases. The deal was structured to be accretive to non-GAAP diluted EPS starting in 2027, with the long-term success hinging on EMPAVELI's ramp-up and a successful felzartamab readout.
Gilead Has Fallen 11% From Its 52-Week High. Is Now the Time to Buy GILD?
Gilead Sciences (GILD) stock has dropped 11% from its 52-week high, prompting investors to question if this presents a buying opportunity. The company recently made two major acquisitions, with the primary deal acquiring Arcellx for its CAR T-cell therapy anito-cel, awaiting FDA approval. Despite an expanded balance sheet, a strong HIV franchise, and multiple upcoming commercial launches targeted for 2026, the company faces risks like potential delays in drug approvals and impacts from the Inflation Reduction Act on Biktarvy's revenue.
Gilead Extends Tender Offer for Arcellx as Biotech M&A Sentiment Faces a Reality Check
Gilead Sciences has extended its tender offer to acquire Arcellx until April 24, 2026, after only 7.5% of Arcellx shares were tendered by the initial deadline. This delay highlights increasing caution among investors and stricter regulatory scrutiny in the biotech M&A market, despite the deal's strategic importance to Gilead's oncology expansion. The situation serves as a case study for the 2026 biotech M&A landscape, where contingent value rights are frequently used to mitigate risk.
RTX Climbed 50% Last Year & Analysts See $216 as the Next Stop
RTX Corporation (RTX) is experiencing strong demand with a record $268 billion backlog and positive EPS guidance for 2026. The company secured a $6.6 billion F135 production contract and its defense unit posted significant bookings, contributing to a robust financial outlook. While analysts maintain a mean price target of $216.34, the valuation model suggests the stock is fairly valued, with growth driven by engine programs and increased munitions production, though GTF engine delivery constraints pose a primary risk.
Kelleher Financial Advisors Increases Holdings in Gilead Sciences, Inc. $GILD
Kelleher Financial Advisors significantly increased its stake in Gilead Sciences, Inc. by 1,954.1% during the fourth quarter, owning 8,586 shares valued at $1,054,000. Other institutional investors also adjusted their positions in the biopharmaceutical company, while company insiders made several sales of stock. Analysts maintain a "Moderate Buy" consensus rating with an average target price of $157.62 for GILD.
Meridian Investment Counsel Inc. Has $3.94 Million Stock Holdings in Gilead Sciences, Inc. $GILD
Meridian Investment Counsel Inc. significantly increased its stake in Gilead Sciences (NASDAQ:GILD) by 51.7% in the fourth quarter, now holding 32,120 shares valued at approximately $3.94 million, representing 0.9% of its portfolio. Gilead reported strong Q4 earnings, beating expectations, and raised its quarterly dividend to $0.82 per share. Analyst sentiment remains positive, with a consensus "Moderate Buy" rating and an average price target of $157.62.
Perpetual Ltd Raises Position in Gilead Sciences, Inc. $GILD
Perpetual Ltd significantly increased its stake in Gilead Sciences, Inc. by 117.9% in Q4, bringing its total holdings to 28,498 shares valued at $3.498 million. The biopharmaceutical company has a "Moderate Buy" consensus rating from analysts, with a target price of $157.62, and recently raised its quarterly dividend to $0.82. Despite some insider selling, institutional investors own a substantial portion of the company's stock.
Gilead Sciences, Inc. (NASDAQ:GILD) Given Consensus Rating of "Moderate Buy" by Analysts
Gilead Sciences (NASDAQ:GILD) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $157.62. The company recently exceeded quarterly earnings and revenue estimates, raising its FY2026 guidance, and increased its quarterly dividend. While insiders have sold shares, institutional investors have significantly increased their positions, now owning 83.67% of the stock.
5 Fastest Growing European Stocks to Invest In
This article highlights Galapagos NV (NASDAQ: GLPG) as one of the fastest-growing European stocks. Galapagos recently entered a binding agreement with Gilead Sciences for the acquisition of Ouro Medicines, which will give Galapagos access to new T cell engager therapies and intellectual property, along with significant financial flexibility. The company also announced a proposed appointment for a new non-executive independent director and future chair of the board for shareholder approval.
Sunshine Biopharma (NASDAQ: SBFM) 2025 revenue reaches $36.3M
Sunshine Biopharma Inc. reported increased revenues of $36.3 million in 2025, primarily driven by expanded generic drug sales in Canada through its Nora Pharma subsidiary. Despite the revenue growth, the company remains unprofitable, recording a net loss of $5.98 million as it continues to invest in its pipeline of 71 generic drugs and proprietary drug development programs for cancer and SARS coronaviruses. The company ended 2025 with $9.12 million in cash, which it anticipates will fund operations for approximately 18 months.
Gilead Sciences, Inc. $GILD Position Reduced by Aberdeen Group plc
Aberdeen Group plc reduced its stake in Gilead Sciences (NASDAQ:GILD) by 12% in the fourth quarter, selling 162,368 shares. Despite this, Gilead reported strong financial results, beating quarterly estimates with $1.86 EPS and $7.93 billion in revenue, and has issued positive FY2026 guidance. The company also increased its quarterly dividend to $0.82 per share.
Barclays takes neutral stance on Gilead Sciences (GILD) despite strategic refocus
Barclays has maintained a Neutral rating on Gilead Sciences (GILD) with a $95.00 price target, despite the company's strategic refocus on oncology and HIV. The analyst acknowledged Gilead's progress in these areas but indicated a need for further pipeline development, particularly in innovative oncology assets, to justify a more bullish outlook. The rating reflects a balanced view of the company's current strengths and future growth challenges.
Key facts: Gilead Extends Arcellx Deal; $115+CVR; HIV Coverage Varies
Gilead has extended its tender offer for Arcellx until April 24, 2026, for $115 cash per share plus a contingent value right of up to $5 if anito-cel reaches $6 billion in sales by 2029. Approximately 4.39 million shares have been tendered in the deal, valued at around $7.8 billion, with closing expected in Q2 2026. Separately, Gilead Sciences' long-acting HIV prevention injection faces variable insurer coverage and patient out-of-pocket costs, as it is not yet explicitly covered by the 2023 U.S. task force guidance.
Bristol Myers Squibb and Gilead Sciences are putting their media accounts into review
Bristol Myers Squibb and Gilead Sciences have initiated a review of their respective media accounts. This development was reported by Ad Age, indicating both major pharmaceutical companies are evaluating their media partnerships. The article notes the date and time of this announcement.
MNPR Stock Price, Quote & Chart | MONOPAR THERAPEUTICS INC (NASDAQ:MNPR)
This article provides a detailed overview of Monopar Therapeutics Inc (NASDAQ: MNPR) stock, including its current price, performance, key statistics, and technical and fundamental analysis ratings from ChartMill. It also covers earnings, analyst forecasts, financial highlights, ownership details, and a company profile outlining its biopharmaceutical focus on cancer treatments.
HF Advisory Group LLC Buys 13,212 Shares of Gilead Sciences, Inc. $GILD
HF Advisory Group LLC increased its stake in Gilead Sciences, Inc. by 66.5%, purchasing an additional 13,212 shares, bringing their total ownership to 33,076 shares valued at $4.06 million. Institutional investors now hold approximately 83.67% of the company's stock, reflecting strong confidence. Analysts rate Gilead as a "Moderate Buy" with a consensus price target of $157.62, following a Q4 earnings beat and a raised quarterly dividend to $0.82.
NuCana plc Stock: Prodrug Technology Platform Targets Oncology Challenges for Long-Term Investor Val
NuCana plc is a clinical-stage biopharmaceutical company leveraging its proprietary ProTide prodrug technology to improve the delivery and efficacy of nucleoside analog drugs in oncology. The company's pipeline includes Nadacomotide (NUC-3373) for colorectal cancer and Acelarin (NUC-1031) for broader solid tumor applications. NuCana's strategy focuses on addressing limitations in existing cancer treatments, positioning it as an investment opportunity for those seeking exposure to early-stage biotech innovation with potential long-term value, particularly for North American investors.
NuCana plc Stock: Prodrug Technology Platform Targets Oncology Challenges for Long-Term Investor Value
NuCana plc, a clinical-stage biopharmaceutical company, utilizes its proprietary ProTide technology to enhance the delivery and efficacy of nucleoside analog cancer drugs, targeting unmet medical needs in oncology. The company's pipeline includes Nadacomotide (NUC-3373) for colorectal cancer and Acelarin (NUC-1031) for broader solid tumor applications, with earlier-stage candidates also in development. North American investors can access NuCana shares (NCNA) on NASDAQ, offering exposure to a company with a focused development strategy in the growing oncology market, though trial risks and funding remain key watchpoints.
GSK plc (ADR) Stock: ViiV Healthcare Ownership Restructured as Pfizer Exits, Strengthening GSK's HIV
GSK plc has restructured the ownership of its HIV-focused subsidiary, ViiV Healthcare. Pfizer Inc. has fully exited its stake, while Shionogi & Co. has increased its economic interest to 21.7% in a $2.125 billion deal. GSK retains a 78.3% majority, eliminating a prior put option liability and solidifying its leadership in the HIV treatment market, a strategic move beneficial for shareholders.
Banque Pictet & Cie SA Purchases 142,543 Shares of Gilead Sciences, Inc. $GILD
Banque Pictet & Cie SA significantly increased its stake in Gilead Sciences, acquiring an additional 142,543 shares to reach a total of 227,007 shares valued at $27.86 million. This comes as Gilead reported strong Q4 earnings, beating expectations, and raised its quarterly dividend. The article also details other institutional investments, insider trading activity, and a "Moderate Buy" consensus rating from analysts with an average price target of $157.62.
Allspring Global Investments Holdings LLC Purchases 71,872 Shares of Gilead Sciences, Inc. $GILD
Allspring Global Investments Holdings LLC significantly increased its stake in Gilead Sciences (NASDAQ:GILD) by 24.6% during the fourth quarter, acquiring 71,872 additional shares. This brings their total holdings to 363,563 shares, valued at approximately $44.21 million. Despite this institutional vote of confidence, insiders have been net sellers, offloading 299,280 shares worth $42.82 million over the past 90 days.
Gilead Sciences, Arcellx see HSR waiting period expire March 31
Gilead Sciences and Arcellx have cleared the Hart-Scott-Rodino premerger waiting period as of March 31. This information was disclosed by Arcellx in a recent US Securities and Exchange Commission filing. The article highlights this as a key regulatory development.
Gilead Extends Tender Offer To Acquire Arcellx
Gilead Sciences has announced an extension of its tender offer to acquire Arcellx. The brief report indicates this is a continuation of the acquisition process between the two companies, Gilead (GILD) and Arcellx (ACLX).
Galapagos NV, Gilead Sciences strike deal tied to Ouro Medicines acquisition
Galapagos NV and Gilead Sciences have entered into a new agreement related to Galapagos' acquisition of Ouro Medicines. This deal signifies continued collaboration between the two companies, potentially impacting their strategic directions and research pipelines. The specific terms of the agreement and its implications for future drug development or financial arrangements are key aspects of this development.
Gilead extends Arcellx tender offer expiration date
Gilead Sciences has extended the expiration date of its tender offer to acquire Arcellx, Inc. The offer, which seeks to acquire all outstanding shares of Arcellx's common stock, is now set to expire on April 30, 2026, at 5:00 PM ET. This extension allows more time for Arcellx shareholders to tender their shares.
Gilead Extends Tender Offer to Acquire Arcellx
Gilead Sciences, Inc. has extended its tender offer to acquire all outstanding shares of Arcellx common stock. The offer remains at $115.00 per share cash, plus a contingent value right of $5.00 per CVR payable by March 31, 2030, based on Arcellx's anitocabtagene autoleucel product sales. The new expiration date for the tender offer is April 24, 2026, with approximately 7.5% of shares already tendered.
Gilead (NASDAQ: ACLX) extends $115 per‑share tender, CVR pays $5 on condition
Gilead Sciences, Inc. has extended its tender offer for Arcellx, Inc. shares to April 24, 2026, maintaining the offer of $115 per share in cash plus a contingent value right (CVR) that could pay an additional $5 if anito-cel sales reach $6 billion by December 31, 2029. As of March 31, 2026, approximately 7.5% of outstanding shares had been tendered. The deal has received regulatory clearances but is facing stockholder lawsuits alleging disclosure deficiencies.
$115-a-share Arcellx bid gets 3 more weeks as Gilead awaits tenders
Gilead Sciences, Inc. has extended its tender offer to acquire all outstanding shares of Arcellx common stock until April 24, 2026. The offer, which includes $115.00 per share in cash plus a contingent value right (CVR) for an additional $5.00, was previously set to expire on April 2, 2026. As of March 31, 2026, approximately 7.5% of Arcellx's outstanding shares have been validly tendered.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE) and Elevance Health (ELV)
Analysts have issued conflicting ratings for healthcare companies Pfizer (PFE) and Elevance Health (ELV). Pfizer received a "Hold" rating from Bernstein and Citi, with a consensus price target indicating a modest upside. Elevance Health was rated "Buy" by both Bernstein and Cantor Fitzgerald, with a consensus price target suggesting a significant upside.
Arcellx Inc stock hits all-time high at 114.92 USD
Arcellx Inc.'s stock reached an all-time high of $114.92 USD, reflecting a strong 89% total return over the past year and contributing to a $6.74 billion market capitalization. Despite this milestone, InvestingPro analysis suggests the stock is currently overvalued. This surge comes amidst recent analyst downgrades following Gilead Sciences' announced acquisition of Arcellx for $115 per share plus a contingent value right.
Gilead Sciences's Q1 2026 Earnings: What to Expect
Gilead Sciences (GILD) is anticipated to release its Q1 2026 earnings, with analysts projecting a 2.8% EPS increase to $1.86. The company has a strong record of exceeding Wall Street EPS estimates and its stock has outperformed both the S&P 500 and the Healthcare Select Sector SPDR ETF over the past year. Analysts maintain a "Strong Buy" rating for GILD, with an average price target suggesting a 14.2% upside.
Gilead Sciences Inc Stock (GILD) Moved Up by 3.03% on Apr 1: Facts Behind the Movement
Gilead Sciences Inc. (GILD) stock rose 3.03% on April 1, driven by positive analyst sentiment, robust product performance, and strategic acquisitions. Analysts have reiterated "Buy" ratings with high price targets, including a $175 target from UBS. Strong sales growth for products like Yeztugo and the acquisition of Ouro Medicines and Arcellx contributed to investor confidence, despite some product-specific risks.
Gilead Sciences's Q1 2026 Earnings: What to Expect
Gilead Sciences (GILD) is expected to announce its Q1 2026 earnings soon, with analysts projecting an EPS of $1.86, a 2.8% increase year-over-year. The company has a history of exceeding Wall Street's EPS estimates in three of its last four quarters. Analysts maintain a "Strong Buy" rating for GILD, with an average price target indicating a 14.2% upside from current levels.
